Development of Passive Immunotherapies for Synucleinopathies. - Test2 - elhamkhani - TriplyDB

Development of Passive Immunotherapies for Synucleinopathies.

Development of Passive Immunotherapies for Synucleinopathies.

http://www.wikidata.org/entity/Q38679627

about

Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.Recent advances in treating Parkinson's disease.Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Recombinant Antibody Fragments for Neurodegenerative Diseases.Alpha-synuclein and iron: two keys unlocking Parkinson's disease.AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy.Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration.Vaccination strategies in tauopathies and synucleinopathies.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

P2860

Q33701172-A3494A9E-FF1F-42E5-8E3E-AF8E3E3C73D0 Q33776552-F5B4A801-5FFF-46B6-B7BA-869789443AE1 Q34554401-ABD7A0BC-DA98-4BE9-8B1F-8BCD256A0B5C Q38817063-6A8A28DA-72C8-47AD-AAFF-8C16B4476AEB Q38970823-70E98E94-4E84-464E-829F-FF9E7AC9F39D Q39123736-68E24373-AD39-4719-9B78-8E0D526D46F8 Q40052760-3328474E-E8BC-40FD-9B73-F8F5CC85C99B Q40968608-0DEA687C-61BA-4D37-BD06-D92CB9511D98 Q41126307-DCC35E4E-A902-422E-BABD-89A16F631E04 Q46354756-D8701C31-66F1-401C-925C-2D68E81AE428 Q47423589-C4420D7B-577A-466C-BA2B-EAE765B01C98 Q47860105-7BF89852-B340-4FE6-91F3-8E7251985592 Q49987358-65FD6266-FB02-4B19-BBF2-B34534EB5DC2 Q52568381-D71B037E-D903-4DCF-9148-4CC5B4F49DB2 Q54982491-87353685-9142-439D-AE95-2EB0F6D84C0D

P2860

Development of Passive Immunotherapies for Synucleinopathies.

http://www.wikidata.org/entity/Q38679627

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Development of Passive Immunotherapies for Synucleinopathies.

@en

type

label

Development of Passive Immunotherapies for Synucleinopathies.

@en

prefLabel

Development of Passive Immunotherapies for Synucleinopathies.

@en

P1433

Q38679627-4F00D27B-DA0F-4E9E-B7FC-1E55AD005E11

P1476

Q38679627-7274F96D-42D1-438D-8FA8-2A10C77879A0

P2093

Q38679627-0536E8B2-7462-42BC-8D9F-E66A1D057B5D

Q38679627-518481B3-D90A-4872-8BF6-1488BE5F657F

Q38679627-CE157D25-FD95-410F-86BA-F87835A8EE86

P2860

Q38679627-00D6D53F-EBB7-48D3-AA60-1B8A2B77E827

Q38679627-06FA1217-B886-4ED6-803E-F414AE3F7F36

Q38679627-079BD8EE-F325-43A5-B11D-C09F20DDBDE6

Q38679627-0ACF6571-BAA0-4C03-BF41-3D70229C4D2C

Q38679627-0D412ACA-F368-4EAC-A0D9-CB9FC3D7F331

Q38679627-1122D96F-291E-4D07-87C0-0D293E0506FF

Q38679627-1196A82F-1FA1-4056-9881-BF1C833F838E

Q38679627-1EF82731-58E4-498F-905E-44B1459A42B4

Q38679627-21BD1371-3401-48D8-8304-3095B5C23D72

Q38679627-2489777D-82F7-4B75-BDC1-A86623494C64

P304

Q38679627-62922234-C95D-4127-9151-EDFA449DC8A0

P31

Q38679627-91A19156-8365-4EC2-AC1F-5E62E4441936

P356

Q38679627-F78F653E-DB59-4ECB-BF62-0F48174C3E23

P407

Q38679627-93B72558-5EFA-4572-8796-4FD2E5CDCB92

P433

Q38679627-184E0783-7EDC-4625-B734-85E17BCF2B97

P478

Q38679627-3F59C071-0EDB-48FD-A095-995721169071

P577

Q38679627-58C18F4D-A831-4F69-9C91-451B9A7E4552

P698

Q38679627-329B79C5-6D3B-473B-8305-66FD65C71848

P356

P1433

Movement Disorders

P1476

Development of Passive Immunotherapies for Synucleinopathies.

@en

P2093

Ann-Louise Bergström

http://www.w3.org/2001/XMLSchema#string

Karina Fog

http://www.w3.org/2001/XMLSchema#string

Pekka Kallunki

http://www.w3.org/2001/XMLSchema#string

P2860

The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

The genetics and neuropathology of Parkinson's disease

Alpha-synuclein biology in Lewy body diseases

Staging of brain pathology related to sporadic Parkinson's disease

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

Antibodies against alpha-synuclein reduce oligomerization in living cells

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

P304

203-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26481

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26704735

http://www.w3.org/2001/XMLSchema#string